Phenylboronic Acid-Modified and ROS-Responsive Polymeric Nanoparticles for Targeted Anticancer Drug Delivery

The specific targeted drug delivery is crucial for antitumor therapy. In this study, phenylboronic acid (PBA)-modified and ROS-responsive biomimetic polymeric nanoparticles have been developed for the targeted delivery of the antitumor drugs. Nanoparticles were constructed by encapsulating doxorubicin (DOX) through the self-assembly of phenylborate pinalol conjugated dextran, followed by erythrocyte camouflage and PBA modification. The particulate size of nanoparticles was 128.3 ± 11.0 nm, which increased slightly to 171.0 ± 10.4 nm after erythrocyte camouflage and PBA modification. The nanoparticles showed sustained and ROS-triggered drug release in vitro. They had excellent colloidal stability in PBS and 10% FBS due to the erythrocyte camouflage, which can help to prolong their blood circulation time. The cellular uptake of nanoparticles was remarkably enhanced due to PBA modification, and the inhibition of cell migration and cell invasion was also promoted. The nanoparticle system can effectively promote the apoptosis of B16F10 cells and show a good antitumor effect in vitro. Thus, this PBA-modified and ROS-responsive biomimetic nanoparticle system has promising application prospects as a tumor-targeted drug delivery system.